pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 4·1 min read
save

Two Michigan Cyclospora Deaths Reported as Eli Lilly Expands Special Retatrutide Access

Aug 4, 2026·read at STAT ↗RegulatoryNeutral

Two people in Michigan have died after contracting cyclospora, a parasitic infection that is rarely fatal but can be severe for those with underlying health conditions. State health officials confirmed these are the first confirmed deaths in the United States linked to the parasite.

The outbreak was traced to contaminated iceberg lettuce, which has since been recalled. Health officials warned that dehydration and intestinal illness from the infection likely worsened the victims' pre‑existing conditions.

Separately, Eli Lilly announced it will broaden special access to its experimental drug retatrutide, following a recent case where a 79‑year‑old patient received the therapy under a compassionate‑use program.

The company’s move aims to provide additional treatment options while the drug continues its regulatory review, signaling ongoing interest in its potential benefits for weight management and metabolic disease.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Trans federal employees sue over revoked health coverage”

read at STAT ↗
1,019 words · retrieved Aug 4
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ELI LILLY CO3LILLY3GILEAD
drugs
Obesity
topics
Infectious Disease3Psychiatry & CNS2Endocrinology & MetabolismObesityVaccineVaccines

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Sling reels in $123M; Circle gathers $92.5MFierce Biotech
  • 3d agoSionna says good-bye to 46% of staffers, including execBioSpace
  • Jun 30Half of states sue over Medicaid work requirementsSTAT
  • Jun 1CDC says containing the spread of Ebola is top prioritySTAT